GLP-1
In late March, Novo Nordisk broke ground on a new manufacturing facility in rural Clayton, North Carolina.
Getting patients to adhere to long-term treatments can be difficult. There are a number of new therapies that will monitor whether or not patients are sticking to their regimen.
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology franchise.
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
In an already competitive diabetes market, Novo Nordisk may have gained a significant edge with the results of its Phase III trial of GLP-1 drug oral semaglutide.
A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31.
The trial was conducted at Rigshospitalet, University of Copenhagen, Denmark, one of the world’s leading centers for the treatment of SBS and top-line results were reported in June 2017
3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.
PRESS RELEASES